BLSM (BlossomHill Therapeutics) Ending Cash Position: $136.68 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics Ending Cash Position?

BlossomHill Therapeutics BLSM -0.06% 8 Ending Cash Position is $136.68 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

BlossomHill Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $136.68 Mil.

BlossomHill Therapeutics's quarterly Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($100.15 Mil) and increased from Dec. 2024 ($100.15 Mil) to Dec. 2025 ($136.68 Mil).

BlossomHill Therapeutics's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($100.15 Mil) and increased from Dec. 2024 ($100.15 Mil) to Dec. 2025 ($136.68 Mil).

BlossomHill Therapeutics Ending Cash Position Related Terms

BlossomHill Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Ending Cash Position Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Ending Cash Position
100.15 136.68

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Ending Cash Position 100.15 136.68
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BlossomHill Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=100.147+36.535
=136.68

BlossomHill Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=100.147+36.535
=136.68

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $136.68 Mil mean?
BlossomHill Therapeutics (BLSM) has a Ending Cash Position of $136.68 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Ending Cash Position too high?
BlossomHill Therapeutics' current Ending Cash Position is $136.68 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Ending Cash Position compare to ?
BlossomHill Therapeutics' Ending Cash Position of $136.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Ending Cash Position is $136.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Ending Cash Position of $136.68 Mil. The current Ending Cash Position is $136.68 Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Ending Cash Position is $136.68 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price